RHJA
CLVS

Rice Hall James & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Rice Hall James & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-208,053
Closed -$3.09M – 293
2019
Q2 		$3.09M Sell
208,053
-14,112
-6% -$255K 0.1% 137
2019
Q1 		$5.51M Buy
222,165
+11,743
+6% +$294K 0.18% 127
2018
Q4 		$3.78M Buy
210,422
+61,210
+41% +$1.25M 0.14% 129
2018
Q3 		$4.38M Sell
149,212
-4,903
-3% -$190K 0.16% 121
2018
Q2 		$7.01M Buy
154,115
+6,036
+4% +$294K 0.25% 111
2018
Q1 		$7.82M Buy
148,079
+429
+0.3% +$25K 0.31% 99
2017
Q4 		$10M Buy
147,650
+25,985
+21% +$1.82M 0.39% 92
2017
Q3 		$10M Sell
121,665
-4,748
-4% -$376K 0.44% 88
2017
Q2 		$11.8M Buy
126,413
+25,487
+25% +$1.56M 0.51% 83
2017
Q1 		$6.43M Sell
100,926
-3,382
-3% -$206K 0.31% 96
2016
Q4 		$4.63M Sell
104,308
-1,899
-2% -$66.8K 0.23% 97
2016
Q3 		$3.83M Buy
106,207
+11,613
+12% +$249K 0.2% 102
2016
Q2 		$1.3M Buy
94,594
+1,716
+2% +$25.1K 0.07% 231
2016
Q1 		$1.78M Buy
92,878
+3,855
+4% +$81.6K 0.1% 189
2015
Q4 		$3.12M Buy
89,023
+39,015
+78% +$2.52M 0.18% 117
2015
Q3 		$4.6M Buy
50,008
+20,516
+70% +$1.78M 0.3% 81
2015
Q2 		$2.59M Sell
29,492
-2,863
-9% -$245K 0.15% 150
2015
Q1 		$2.4M Buy
+32,355
New +$2.28M 0.14% 165

Other funds holding CLVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Rice Hall James & Associates's CLVS Position: Q3 2019 in Review

Rice Hall James & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 208,053 shares — an estimated $3.09M sold.

Rice Hall James & Associates first reported a position in CLVS in Q1 2015 and held it in 18 quarters. The position peaked at $11.8M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

  • Rice Hall James & Associates reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 208,053 Clovis Oncology, Inc. shares in Q3 2019, an estimated $3.09M.
  • Rice Hall James & Associates first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 18 quarters.
  • Rice Hall James & Associates's Clovis Oncology, Inc. position peaked at $11.8M in Q2 2017.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Rice Hall James & Associates's 13F filing for Q3 2019, filed 30 Oct 2019.